Business · 07/09/2023Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Regeneron for Rare Pediatric Disease Product
Summary
The FDA has awarded a priority review voucher to Regeneron Pharmaceuticals, Inc. for its rare pediatric disease product VEOPOZ (pozelimab-bbfg), following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →